A combination shot for Flu and Covid -10, using Messenger RNA, has created antibodies in a study, but US government regulators want to see data on whether new vaccines protect people from getting sick.
In a study published on Wednesday, researchers in vaccine -makers mode say that the new combo shot has reacts to the strongest resistance against the most strong resistance against the existing standlone shots between Covid -1 and 50 or older. Side effects were the pain, fatigue and headache of the injection site. Modana had earlier summarized the results of the agency-sponsored trial out of 8,000 people.
MRNA technology is used in approved Covid -10 and RSV shots, but not yet approved for the flu shot. Moda believes that MRNA can speed up the production of flu shots compared to the traditional taid processes that use the giant VAT of chicken eggs or cells. Researchers wrote in the study published in the Journal of the American Medical Association that a combo shot could improve the vaccine rate.
Dr. Greg Poland, who studied vaccine in Mayo Clinic and was not involved in new research, said he was not sure that a combo shot would be popular. And when the flu seasonal waves arrives, Covid -10 has spread throughout the year, Poland said how shots are strengthened by challenging shots to keep the shots strong.
He will also want to see the data of the new shot and how much protected from hospitalization.
Searchs indicate the protection of short -term diseases, based on measuring antibodies in the blood after 29 days.
Last week, after the food and drug administration requested further direct management, Moda pushed the target to its vaccine’s approval at 2026: how much the shot reduced the risk of the disease.
Poland said, “I agree with the FDA that it is important to look at the effectiveness data,” Poland said.
Health Secretary Robert F. Kennedy has expressed doubts about the protection of the MRNA vaccines, but Modner President Stephen Hogh last week told investors to invest in investors in investors that talking to the FDA was productive and “usual business”.
Also last week, Novovax said that the FDA agency had made uncertainty about other vaccine updates and asked the company to manage a new clinical trial of its protein -based Covid -19 vaccine.
___
Associated Press Health and Science Department has received the support of the Science and Educational Media Group and Robert Wood Johnson Foundation of the Hughes Medical Institute. AP is the sole responsible for all content.
Leave a Reply